Gufic Biosciences faces ₹15.64 lakh penalty; plans appeal.
Gufic Biosciences Limited received an order imposing a total penalty of ₹15,64,052 for excess Input Tax Credit and short payment of tax liability for FY19-FY23. The company plans to appeal the order, stating it will not materially impact operations.
The penalty amount is relatively small for the company's size, and the company has stated it will not have a material impact on its operations.
The company received a penalty but plans to appeal, and states it will not materially impact operations. The outcome of the appeal is uncertain.
Gufic Biosciences Limited has received an order under Section 74 of the CGST Act, 2017, and UPGST Act, 2017, along with Section 20 of the IGST Act, 2017. The order imposes a penalty of ₹15,35,080 for alleged excess Input Tax Credit (ITC) claimed and a penalty of ₹28,972 for short payment of tax liability.
The penalties are related to the financial years 2018-19 to 2022-23. The company has stated that it is not satisfied with the order and intends to file an appeal before the concerned authority. Gufic Biosciences confirms that this intimation has no material impact on its financial operations or other activities. The order was dated December 26, 2025, and received by the company via email on December 27, 2025. The authority issuing the order is the Office of the Superintendent CGST, Range-07, Division II, Ghaziabad.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.